NCT06220214
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Jul 31, 2026 to Jul 31, 2027
- Eligibility criteria expanded, about 6 words
- Study completion pushed from Aug 31, 2026 to Aug 31, 2027
- Interventions: CEDBT (Diagnostic Test), CEDM (Diagnostic Test), Omnipaque 350mgI/mL Solution for Injection (Drug) to CEDBT (Diagnostic Test), CEDM (Diagnostic Test), Omnipaque 350mgI/mL Solution for Injection (Drug)
- Minor Study completion date: Aug 2026 to Aug 31, 2026
- Start date changed from estimate of Mar 23, 2024 to Mar 6, 2024
Notable Phase: Not applicable to Early Phase 1v2 Show 4 more changesShow less
- Trial status: Not Yet Recruiting to Recruiting
- Start date: Jan 2024 to Mar 23, 2024
- Study sites: 0 to 1
- Interventions: CDBT (Diagnostic Test), CEDM (Diagnostic Test) to CEDBT (Diagnostic Test), CEDM (Diagnostic Test), Omnipaque 350mgI/mL Solution for Injection (Drug)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Accuracy of (CEDM+CEDBT) to predict NAC treatment effects
Timeframe: Immediately after definitive breast surgery, up to 24 weeks
Secondary (1)
Accuracy of (CEDM+CEDBT) to detect residual tumor compared with standard of care MRI
Arms and interventions
CEDM + CEDBTExperimental
Participants undergo CEDM + CEDBT imaging after every 4-6 cycles of neoadjuvant chemotherapy prior to surgery (imaging may occur up to 2 times)
Diagnostic tests: CEDM, CEDBT
Drugs: Omnipaque 350mgI/mL Solution for Injection
Sites
1 site in 1 country
- Stony Brook Breast CenterStony Brook, New York, United States